Zante Greg's Form 4 filing
Viking Therapeutics, Inc. (VKTX) · filed Jan 4, 2024
- Accession no.
- 0001209191-24-000929
- Filed
- Jan 4, 2024
- Trade date
- Jan 3-4, 2024
- Filing delay
- 1 day
- Rule 10b5-1 plan
- Not checked
This filing lists 6 non-derivative transactions and 1 derivative transaction. Open-market sales total $268.5K. It was filed 1 day after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Zante GregCIK 0001264949 | Officer (Chief Financial Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jan 3, 2024 | Common Stock, par value $0.00001 per share | AGrant or awardAcquired | +28,334 | $0.00 | $0 | 188,724 | Direct | |
| Jan 3, 2024 | Common Stock, par value $0.00001 per share | FTax withholdingDisposed | −18,233 | $17.40 | −$317,254.2 | 170,491 | Direct | |
| Jan 3, 2024 | Common Stock, par value $0.00001 per share | AGrant or awardAcquired | +70,000 | $0.00 | $0 | 240,491 | Direct | |
| Jan 3, 2024 | Common Stock, par value $0.00001 per share | FTax withholdingDisposed | −30,889 | $17.40 | −$537,468.6 | 209,602 | Direct | |
| Jan 4, 2024 | Common Stock, par value $0.00001 per share | FTax withholdingDisposed | −13,872 | $18.58 | −$257,741.76 | 195,730 | Direct | |
| Jan 4, 2024 | Common Stock, par value $0.00001 per share | SSaleDisposed | −15,000 | $17.90F6 | −$268,500 | 180,730 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jan 3, 2024 | Common Stock | AGrant or awardAcquired | +155,000 | $0.00 | $0 | 155,000 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F6
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.72 to $18.14, inclusive. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer full information regarding the number of shares sold at each separate price.
Referenced by the price of 1 transaction in Table I.